![]()
|
|
||||||||
J Biol Chem, Vol. 275, Issue 3, 1685-1690, January 21, 2000
,
,
From the
Department of Biochemistry and Institute for
Medical Sciences, Chonbuk National University Medical School,
Chonju, 561-182 Korea, § Division of Molecular Life
Science and Center for Cell Signaling Research, Ewha Women's
University, Seoul, 120-750 Korea, and ¶ Samsung Biomedical
Research Institute and Sungkyunkwan University, School of Medicine,
Suwon, 440-746 Korea
| |
ABSTRACT |
|---|
|
|
|---|
CD38 ligation has been shown to induce activation
of intracellular signaling cascade in T lymphocytes through a
Lck-dependent pathway. However, it is not clear how Lck
initiates the CD38-mediated signaling process. In the present study, we
showed that CD38 and Lck were physically associated through the
cytoplasmic tail and the Src homology 2 domain, respectively. This was
evidenced by coimmunoprecipitation of Lck with CD38 and Lck with
isolated CD38 cytoplasmic domain from T cell lysate, cell lysate of
COS-7 cells cotransfected with cDNAs of Lck and CD38, or a mixture
of in vitro translated CD38 and Lck. Because the CD38
cytoplasmic domain does not contain any tyrosine residue, the
interaction should be independent of phosphotyrosine. The interaction
was further confirmed by in vitro interaction between a
purified Lck Src homology 2 domain and a nonphosphosynthetic peptide
corresponding to the membrane proximal region of the CD38 cytoplasmic
domain. In addition, CD38 ligation resulted in an elevated tyrosine
kinase activity of the CD38-associated Lck and ultimate activation of
interleukin-2 gene transcription. Furthermore, expression of a
kinase-deficient Lck mutant suppressed interleukin-2 gene activation in
a dose-dependent manner. These results strongly suggested
that CD38 ligation indeed tranduced signals for T cell activation using
its associated Lck.
CD38 is a type II transmembrane glycoprotein with a long
C-terminal extracellular domain and a short N-terminal cytoplasmic tail
(1). The extracellular domain of CD38 has bifunctional enzyme
activities that catalyze synthesis of cyclic ADP ribose from
nicotinamide adenine dinucleotide (NAD) and hydrolysis of cyclic ADP
ribose to adenosine diphosphoribose (1-3). Cyclic ADP ribose is a
novel Ca2+ mobilizer in different eukaryotic cells where it
can modulate the intracellular calcium levels by releasing it from
ryanodine-sensitive intracellular stores (4-10).
In addition to the catalytic activities of the extracellular domain,
the CD38 cytoplasmic domain seems to independently transduce activation
signals. CD38 ligation with an agonistic anti-CD38 monoclonal antibody
(mAb)1 stimulates
proliferation of B and T lymphocytes (11-13) and increases tyrosine
phosphorylations of a set of intracellular proteins (14-17). Targets
for the CD38-mediated tyrosine phosphorylation and activation of
downstream signaling cascade in T cells include the TCR/CD3 In the present study, it is demonstrated that CD38 and Lck molecules
are directly associated through a phosphotyrosine-independent interaction between the cytoplasmic domain of the former and the SH2
domain of the latter. Upon CD38 ligation, tyrosine kinase activity of
the associated Lck is up-regulated and relays signals to induce the
ultimate activation of IL-2 gene transcription.
Cell Culture and Antibodies--
Adherent (COS-7) and suspension
(Jurkat, J.Cam1) cells were maintained in Dulbecco's modified
Eagle's medium and RPMI (Life Technologies, Inc.) supplemented with
10% fetal bovine serum. T lymphocytes were isolated from spleens of
4-week-old BALB/c mice by using a nylon wool column as described (18).
Antibodies were purchased from Pharmingen (murine monoclonal
anti-CD38), Immunotech (T16, human monoclonal anti-CD38), Serotec
(F(ab')2 goat anti-rat IgG), UBI (monoclonal 4G10
anti-phosphotyrosine, polyclonal anti-Lck), Sigma (anti-rat and mouse
IgG-agarose), IBI-Kodak (monoclonal anti-FLAG epitope), and Amersham
Pharmacia Biotech (anti-GST). For cross-linking of CD38, T cells were
incubated with anti-CD38 mAb (10 µg/107 cells) or control
rat IgG for 30 min on ice. After removal of unbound antibodies, cells
were resuspended in serum-free RPMI and cross-linked for 5 min at
37 °C with soluble F(ab')2 goat anti-rat IgG (20 µg/107 cells). Cells were immediately lysed in a lysis
buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl,
1% digitonin, 1 mM EGTA, 1 mM
phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin, 10 µg/ml
aprotinin, 10 µg/ml pepstatin, 100 µM
Na3VO4, 50 mM NaF) and centrifuged
at 20,000 × g for 30 min at 4 °C, and resulting
supernatant was used for further analysis.
Cloning and Expression of Recombinant CD38 and
Lck--
cDNAs encoding human CD38 and Lck were prepared by
reverse transcriptase-polymerase chain reaction and cloned into
pFLAG-CMV2 (IBI, Kodak), pRc/CMV (Invitrogen), and pCDNAI vectors.
A kinase-defective mutant Lck (Lck.A273) was generated by replacing a
coding sequence of the lysine 273 (AAG) with that of alanine (GCG)
using the QuickChangeTM site-directed mutagenesis system
(Stratagene). A sequence of mutated nucleotide was confirmed by DNA
sequencing. The IL-2-Luc reporter contains the luciferase gene
downstream from the IL-2 promoter region, including 548 base pairs 5'
of the transcription start site and was generated by subcloning a
HindIII fragment from the IL-2 promoter into the
HindIII site of pGL3-basic vector (Promega) (19). An
expression vector for the CD38 cytoplasmic domain alone was constructed
by inserting a polymerase chain reaction fragment encoding the specific
region into a pFLAG-CMV2 vector. Construction and preparation of
GST-fused Lck subdomains were described elsewhere (20). GST-fused SH2
domains of Src and Crk and N-terminal SH2 domains of GTPase-activating
protein, phospholipase C- Immunoprecipitation and Immunoblotting--
For
immunoprecipitation, cell lysates were incubated for 1 h at
4 °C with anti-CD38 mAb or 4G10 anti-phosphotyrosine antibody and
further incubated for 30 min with anti-rat or anti-mouse IgG-agarose. Immunoprecipitates were washed three times with the lysis buffer, and
proteins were separated on a 10% SDS-PAGE. After transfer to a
nitrocellulose membrane, protein bands were visualized by immunoblotting using specific antibodies, horseradish
peroxidase-conjugated anti-mouse or anti-rabbit IgG antibodies
(Advanced Biochemicals Inc., Korea), and an ECL substrate kit (Amersham
Pharmacia Biotech). Similarly, Lck subdomain binding proteins were
analyzed; after preclearing with GST-glutathione Sepharose beads or
anti-FLAG (M2) affinity gel, cell lysates were incubated with purified
GST fusion proteins (~5 µg), and bound proteins were precipitated with glutathione-Sepharose beads and analyzed by immunoblotting.
Real Time Binding Analysis--
Three peptides corresponding to
amino acids 1-10 (ANCEFSPVSG), 5-15 (SPVSGDKPCC), and 11-20
(DKPCCRLSRR) of CD38 were synthesized at Korea Basic Science Center and
subsequently purified on C18 reversed phase high pressure liquid
chromatography. Purified GST-Lck.SH2 domain fusion protein was
covalently coupled to the dextran surface of a BIAcore sensorchip. The
synthetic peptide solution (0.25 mg/ml) was injected onto immobilized
Lck SH2 surface, and binding was measured as responses from 25 s
postinjection relative to a baseline determined immediately before injection.
In Vitro Transcription and Translation--
Recombinant
plasmids, pRc/CMV containing human CD38 cDNA and pCDNAI
containing human LCK cDNA, were linearized with restriction enzymes, XhoI and XbaI, respectively. In
vitro transcription was performed using RiboMAXTM Large Scale RNA
production system, and in vitro translation was performed
with resulting RNA products using a rabbit reticulocyte lysate system
according to the manufacturer's instructions (Promega).
Direct Interaction of CD38 and Lck--
CD38 ligation induces a
rapid increase in Lck-dependent tyrosine phosphorylation of
a set of cellular proteins; however, a mechanism through Lck is
recruited to the CD38-signaling complex is not known (17). One
possibility is that Lck directly associates with CD38, and upon CD38
ligation, the associated Lck is activated to phosphorylate its cellular
substrates. To examine the possibility, coimmunoprecipitation of CD38
with Lck was analyzed in cell lysates of purified murine T cells.
Interestingly, Lck was found in an immune complex precipitated by a
specific anti-murine CD38 mAb (clone 90, Pharmingen) but not by an
immunoprecipitate of an isotype matched control Ab (Fig.
1A, lanes 2 and
1, respectively). Furthermore, when Lck was
precleared from the cell lysates using anti-Lck antiserum, CD38 no
longer coprecipitated with Lck (Fig. 1A, lane 3).
These results indicate that Lck is associated, either directly or
indirectly, with CD38 in T cells.
When mixed together, in vitro translation products of
[35S]methionine labeled Lck and CD38 were
coimmunoprecipitated by either anti-CD38 mAb or anti-Lck antiserum
(Fig. 1B, lanes 2 and 4). In addition,
Lck and CD38 were also coimmunoprecipitated from lysates of COS-7 cells
ectopically expressing both CD38 and Lck (Fig. 1C).
Interestingly, expression of only the cytoplasmic domain of CD38 was
sufficient to precipitate the cotransfected Lck (Fig. 1C).
These results strongly indicate that the cytoplasmic domain of CD38
interacts directly with Lck and that the interaction does not require
any other T cell-specific component.
Interaction of the Cytoplasmic Domain of CD38 and the SH2 Domain of
Lck--
To delineate subregion(s) of Lck required for association
with CD38, GST fusion proteins containing the N-terminal unique region,
SH3 domain, SH2 domain, or a combination of these subregions of Lck
were examined for their ability to associate with CD38 (Fig.
2). To this end, cell lysates of COS-7
cells expressing either FLAG epitope-tagged wild type CD38
(FLAG-CD38wt) or the cytoplasmic domain of CD38 (FLAG-CD38cyt) were
incubated with purified GST fusion proteins. FLAG-CD38wt was
immunoprecipatated using anti-FLAG mAb, and the associated GST-fused
Lck subdomain(s) was examined by immunoblot analysis using an anti-GST
antiserum (Fig. 2C). Interestingly, both FLAG-CD38wt and
FLAG-CD38cyt interacted well with GST fusion proteins containing the
Lck SH2 domain (1-224, 65-224, and 119-224) but not with GST fusion
proteins of other subdomains. Furthermore, when GST fusion proteins
were precipitated by glutathione-Sepharose beads, CD38 was clearly
detected only in the precipitates of GST fusion proteins containing the
Lck SH2 domain (Fig. 2D). The same experiments using GST
fusion proteins containing SH2 domains of other proteins failed to show
any interaction with CD38 (Fig. 2E). Taken together, these
data showed that the cytoplasmic domain of CD38 specifically associated
with the Lck SH2 domain.
Interaction of the CD38 cytoplasmic domain and the Lck SH2 domain was
further confirmed by measuring real time binding between purified
GST-fused Lck SH2 domain and synthetic peptides derived from the CD38
cytoplasmic domain (Fig. 3A).
Interestingly, a peptide corresponding to amino acid residues 11-20 of
CD38 showed clear interaction with immobilized GST-Lck SH2 domain,
whereas N-terminal peptides did not. Furthermore, the interaction of
CD38 with the purified GST-fused Lck SH2 domain was inhibited by a
peptide derived from amino acid residues 11-20 of CD38 dose
dependently, but not by N-terminal peptides or a random amino acid
sequence peptide (Fig. 3B). Thus, it is likely that CD38 and
Lck form a complex through the membrane proximal region of the CD38
cytoplasmic domain and the Lck SH2 domain.
Lck Is Essential in CD38-mediated T Cell Activation--
Lck has
an essential role in TCR/CD3-mediated activation of the Ras-MAPK
pathway, which eventually influences IL-2 gene activation in a subset
of T cells (21, 22). CD38 ligation also has been suggested to activate
MAPK and thereby induce slower migration of Lck on SDS-PAGE, probably
because of MAPK-mediated serine phosphorylation of Lck (17). Thus, the
physical interaction of CD38 and Lck may be a mechanism resembling the
mechanism of TCR/CD3-mediated signaling. Indeed, ligation of CD38
substantially increased the tyrosine kinase activity of Lck (Fig.
4A). Furthermore, ligation of
both CD38 and CD3 induced a similar mobility change of CD38-associated Lck (Fig. 4B).
Finally, to examine the requirement of the kinase activity of Lck in
CD38-mediated signaling, we investigated the effects of a kinase
inactive mutant Lck, Lck.A273, which is defective in a part of the ATP
binding site (23, 24). Jurkat T cells were cotransfected with IL-2-Luc
reporter and various amounts of Lck.A273, and the CD38
ligation-mediated IL-2 promoter activation was analyzed. As shown in
Fig. 4C, CD38 cross-linking enhanced IL-2 promoter activity
more than 3-fold over the basal level in Jurkat cells, and this
enhancement was abolished upon coexpression of Lck.A273 in a
dose-dependent manner. However, this mutation did not
affect the interaction with CD38 (data not shown), and the basal IL-2
promoter activity was not affected by coexpression of Lck.A273. These
results suggest that CD38 transduces a signal for IL-2 gene activation
through the associated Lck activation in a manner similar to the
Lck-mediated TCR/CD3 signaling.
In a previous study, it was shown that CD38 ligation induced
Lck-regulated phosphorylation and/or activation of CD3 The SH2 domain is a highly conserved structural module of about 100 amino acid residues and mediates protein-protein interactions (25). In
general, SH2 domains interact with phosphotyrosine residues of a
specific ligand using a well conserved phosphotyrosine binding pocket
(26). However, the CD38 cytoplasmic domain does not have any tyrosine
residues (1), and it binds well to an Arg-154 mutant Lck, which is
defective in the phosphotyrosine binding pocket (Ref. 26 and data not
shown). Thus, the CD38 cytoplasmic domain interacts with the Lck SH2
domain in a phosphotyrosine-independent manner. There are several
reports showing that SH2 domains can also serve as
phosphotyrosine-independent protein binding sites (20, 27-30). The
interaction of some phosphotyrosine-independent ligands with SH2 domain
seemed to depend on extensive phosphorylation on serine/threonine
residues (31-33). However, three serine residues present in the CD38
cytoplasmic domain were not efficiently phosphorylated before and after
CD38 ligation (data not shown). Furthermore, a decapeptide derived from
the membrane proximal region of the CD38 cytoplasmic domain having only
one nonphosphorylated serine residue bound well to the Lck SH2 domain
(Fig. 3). Thus, the CD38 cytoplasmic domain requires neither tyrosine
nor serine phosphorylation for its interaction with the Lck SH2 domain.
At present, it is not clear whether or not the 10 amino acids are the
minimal length required for SH2 domain binding and how the interaction
occurs between such a short non-phosphopeptide and the Lck SH2 domain. Further analysis is needed to better understand this novel interaction mode, which provides a potential way to modulate SH2 domain-mediated protein-protein interaction.
Lck has been known to interact with a few T cell surface molecules
including CD4, CD8, TCR/CD3 Because both CD38 and CD3 activate Lck and utilize it to initiate
downstream signaling cascades, there may be a cross-talk between
signaling pathways transduced by these two distinct T cell surface
receptors. Indeed, CD38 ligation resulted in a sequence of events that
occur during CD3-mediated T cell activation: tyrosyl phosphorylation of
the CD3
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
chain,
ZAP-70, components of Ras-mitogen-activated protein kinase pathway, and
c-Cbl (17). However, CD38 itself lacks intrinsic protein-tyrosine
kinase activity, and such molecular modifications do not occur in a
Lck-deficient Jurkat cell line, J.Cam1 (17). These results indicate
that Lck likely plays an important role in signal transduction through
the cytoplasmic domain of CD38. However, it is unknown how CD38
recruits and uses Lck in transducing signals further downstream in the cell.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1, and p85 phosphatidylinositol 3-kinase
were generous gifts of Dr. Steven E. Shoelson at the Harvard Medical
School. Expressions of CD38 and Lck were achieved by transient
transfection of corresponding plasmids (5 µg) into COS-7 or T cell
lines using DEAE-dextran or SuperfectTM (Quiagen Inc.).
Transfected cells were analyzed after 48 h posttransfection. In vitro transcription and translation of CD38 and Lck were
performed according to manufacturer's instructions using
RiboMAXTM and rabbit reticulocyte lysate systems (Promega).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (25K):
[in a new window]
Fig. 1.
Direct interaction of CD38 and Lck.
A, coimmunoprecipitation of CD38 and Lck. Murine T cells
were prepared, lysed, and immunoprecipitated with a normal mouse IgG
(lane 1) and anti-CD38 monoclonal antibody (lanes
2 and 3), before (lanes 1 and 2)
and after (lane 3) depletion of Lck from the lysate using
anti-Lck antibody. Immunoprecipitates were then analyzed by Western
blot using anti-Lck antibody. The arrow points to the Lck
molecule. B, association of in vitro translated
CD38 and Lck. In vitro translation products of
[S35]methionine-labeled CD38 and Lck (see "Experimental
Procedures") were incubated separately (lanes 1 and
3) or mixed and incubated (lanes 2 and
4) for 4 h at 4 °C. CD38 (lanes 1 and
2) and Lck (lanes 3 and 4) were
immunoprecipitated, and the immune complexes were analyzed on a 10%
SDS-PAGE followed by autoradiography. Arrows point to Lck,
and arrowheads to CD38 molecules. C, interaction
of CD38 and its cytoplasmic tail with Lck in COS-7 cells. COS-7 cells
were cotransfected with cDNAs encoding Lck and wild type CD38
(CD38wt) or cytoplasmic domain of CD38 (CD38cyt). CD38 was
immunoprecipitated from cell lysates before and after Lck depletion.
Lck content in the immunoprecipitates was measured by immunoblot
analysis using ant-Lck Ab. IP, immunoprecipitate.

View larger version (40K):
[in a new window]
Fig. 2.
Association of the CD38 cytoplasmic tail and
the Lck SH2 domain. A, schematic presentation of
FLAG-tagged CD38 (FLAG-CD38wt), isolated CD38 cytoplasmic tail
(FLAG-CD38cyt), and GST fusion proteins of Lck subdomains.
B, bacterially expressed and purified GST fusion proteins.
Fusion proteins were expressed and purified as described under
"Experimental Procedures," and analyzed on a SDS-PAGE by Coomassie
Blue staining. C, interaction of the Lck SH2 domain with
CD38. Lysates of COS-7 cells transfected with cDNAs of FLAG-CD38wt
or FLAG-CD38cyt were incubated with purified GST fusion proteins at
4 °C. FLAG-tagged proteins were immunoprecipitated by anti-FLAG (M2)
antibody, and coprecipitated GST-fused Lck subdomains were measured by
immunoblot analysis using anti-GST Ab. D, GST-fused Lck
subdomains were precipitated by glutathione-Sepharose beads from the
same incubation mixture as in C, and coprecipitated CD38 was
measured by immunoblot analysis using anti-FLAG Ab. E, only
the Lck SH2 domain interacts with CD38. Interaction of CD38 with
GST-fused SH2 domains of various proteins was analyzed as in
C. IP, immunoprecipitate.

View larger version (20K):
[in a new window]
Fig. 3.
Interaction of CD38 cytoplasmic tail peptides
and Lck SH2 domain. Three peptides corresponding to amino acid
residues 1-10 (CD1, ANCEFSPVSG), 6-15 (CD2, SPVSGDKPCC), and 11-20
(CD3, DKPCCRLSRR) of CD38 are shown in the upper panel.
A, peptide solutions (0.25 mg/ml) were injected onto the
immobilized Lck SH2 surface of a BIAcore sensorchip, and binding was
measured as responses from 25 s postinjection relative to a
baseline determined immediately before injection. RU,
relative units. B, inhibition of CD3 peptide on the
interaction of Lck SH2 with CD38. Each peptide was incubated with GST-
Lck SH2 for 30 min and further incubated with FLAG-CD38wt for 1 h.
GST-Lck SH2 was precipitated with glutathione-Sepharose beads, and
coprecipitated CD38 was detected by anti-FLAG Ab. NA2 is a control
peptide of random amino acid sequence (DAQLDMALDS).

View larger version (29K):
[in a new window]
Fig. 4.
Lck-mediated CD38 signaling for T cell
activation. A, activation of Lck catalytic activity by
CD38 ligation. 5 × 106 Jurkat cells were ligated by
an agonistic anti-CD38 antibody (+) or a control antibody (
) for 10 min and lysed. Lck was immunoprecipitated from the cell lysates and
subjected to in vitro kinase assay in the presence of 100 ng
of enolase in 50 mM HEPES (pH 8.0), 10 mM
MgCl2, 10 mM ATP, and 10 µCi of
[32P]ATP. After a 20-min incubation at room temperature,
reaction was stopped by adding same volume of 2X SDS-sample buffer.
Samples were boiled for 3 min, separated on a 10% SDS-PAGE, and
visualized by autoradiography. B, Lck gel shift induced by
CD38 cross-linking. Partially purified murine T cells were treated on
ice with anti-CD38, anti-CD3, or mouse IgG for 30 min and then
secondary antibody for 5 min at 37 °C as described under
"Experimental Procedures." Lck was immunoprecipitated from the cell
lysates using anti-CD38 or anti-phosphotyrosine Ab, and its mobility
was measured on a 9% SDS-PAGE, followed by immunoblot analysis using
anti-Lck Ab. Arrows indicate two species of Lck molecules
with different mobilities at the 56 and 60 kDa regions. C,
Lck is required for the CD38 ligation-mediated activation of IL-2
promoter. 106 Jurkat T cells were cotransfected with 1.0 µg of IL-2-Luc reporter plasmids and indicated amounts of expression
plasmids encoding kinase-defective Lck (Lck.A273). At 24 h
posttransfection, cells were ligated with anti-CD38 antibody and
incubated for an additional 14 h. The experiments were performed
in duplicate three times, and the standard deviations are shown on top
of each bar. I.P., immunoprecipitates.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
, ZAP-70, Ras-mitogen-activated protein kinase pathway, and other signaling molecules in Jurkat T cells (17). However, it was unclear how CD38
ligation recruited Lck to its signaling of downstream cascades. The
present study demonstrated that the cytoplasmic domain of CD38 directly
associated with Lck via its SH2 domain (Figs. 1 and 2) and that
ligation of CD38 up-regulates Lck tyrosine kinase, thereby inducing the
ultimate activation of IL-2 gene transcription (Fig. 4). Thus, the
present data confirm the CD38-induced Lck-dependent signaling and provide further insight of molecular mechanisms involved
in this signaling pathway.
chain, and IL-2R
(34-36), and
distinct subregions of Lck are used for interaction with these molecules (a unique N-terminal region for CD4 and CD8, the SH2 domain
for the tyrosyl-phosphorylated CD3
chain, and the SH1 or SH3 domain
for IL-2R
). Through these interactions, Lck plays important roles in
signaling at different T cell environments. The unique interaction of
CD38 with Lck, therefore, represents another addition to the divergent
roles of Lck in T cell regulation.
chain and ZAP-70, activation of the Ras-Raf-MAPK pathway,
and mobility shift of Lck, likely due to serine phosphorylation by the
activated MAPK (17). In a reverse direction, CD3 cross-linking induced
the same mobility shift of CD38-associated Lck (Fig. 4B).
Interestingly, proper CD38 signaling seemed to require expression of
TCR/CD3 on human T cell surface (37). Thus, some of the CD38-mediated
signaling events might be elicited through signaling machineries shared
with TCR/CD3 and vice versa. However, there are also apparent
differences between outcomes of signaling through CD38 and CD3. For
example, the extents of cytokine production by individual ligation of
these two cell surface receptors are significantly different from one
cytokine to the other (38). Distinct kinetics of Ca2+
mobilization induced by cross-linking of CD38 and CD3 would be another
example (37). Thus, although CD38 and CD3 may share common signaling
components in some part, these two receptors likely use their own
unique mechanisms to transduce distinct signals. The presence of a
signaling pathway unique for CD38 is supported by observations of CD3
expression-independent phosphorylation of c-Cbl (17), the CD38
cytoplasmic domain-independent intracellular tyrosine phosphorylation,
and IL-2 production in myeloid and B cell lines (39, 40). Nevertheless,
CD38 provides an alternative signaling pathway for T cell activation
via its associated tyrosine kinase, Lck. Further investigations of
interaction between the CD38 cytoplasmic domain and the Lck SH2 domain
will shed more light to better understanding of CD38-mediated T cell signaling.
| |
ACKNOWLEDGEMENTS |
|---|
We thank T. Katada, E. Flemington, and W. K. Paik for critically reading the manuscript.
| |
FOOTNOTES |
|---|
* This work was supported by Science & Technology Evaluation Planning Institute Grant 97-N1-02-02-A-04 and the Korea Science and Engineering Foundation Grant 971-0708-061-1.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of
Biochemistry, Chonbuk National University Medical School, Chonju,
561-182 Korea. Tel.: 82-652-270-3083; Fax: 82-652-274-9833; E-mail:
uhkim@moak.chonbuk.ac.kr.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: mAb, monoclonal antibody; IL, interleukin; GST, glutathione S-transferase; PAGE, polyacrylamide gel electrophoresis; Ab, antibody; wt, wild type; cyt, cytoplasmic; MAPK, mitogen-activated protein kinase; SH, Src homology; TCR, T cell receptor.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Jackson, D. G., and Bell, J. I. (1990) J. Immunol. 144, 2811-2815[Abstract] |
| 2. | Zocci, E., Franco, L., Guida, L., Benatti, U., Bargellsi, A., Malavasi, F., Lee, H., and DeFlora, A. (1993) Biochem. Biophys. Res. Commun. 196, 1459-1465[CrossRef][Medline] [Order article via Infotrieve] |
| 3. |
Kim, H.,
Jacobson, E. L.,
and Jacobson, M. K.
(1993)
Science
261,
1330-1333 |
| 4. |
Rusinko, N.,
and Lee, H. C.
(1989)
J. Biol. Chem.
264,
11725-11731 |
| 5. |
Galione, A.,
Lee, H. C.,
and Busa, W. B.
(1991)
Science
253,
1143-1146 |
| 6. |
Takasawa, S.,
Nata, K.,
Yonekura, H.,
and Okamoto, H.
(1993)
Science
259,
370-373 |
| 7. |
Wu, Y.,
Kuzma, J.,
Marechal, E.,
Graeff, R.,
Lee, H. C.,
Foster, R.,
and Chua, N. H.
(1997)
Science
278,
2126-2129 |
| 8. |
Lee, H. C.
(1997)
Physiol Rev.
77,
1133-1164 |
| 9. |
Lee, H. C.,
Walseth, T. F.,
Bratt, G. T.,
Hayes, R. N.,
and Clapper, D. L.
(1989)
J. Biol. Chem.
264,
1608-1615 |
| 10. | Guse, A. H., da Silva, C. P., Berg, I., Skapenko, A. L., Weber, K., Heyer, P., Hohenegger, M., Ashamu, G. A., Schulze-Koops, H., Potter, B. V. L., and Mayr, G. W. (1999) Nature 398, 70-73[CrossRef][Medline] [Order article via Infotrieve] |
| 11. | Funaro, A., Spagnoli, G. C., Ausiello, C. M., Allesio, M., Roggero, S., Delia, D., Zaccolo, M., and Malavasi, F. (1990) J. Immunol. 145, 2390-2396[Abstract] |
| 12. | Santos-Argumedo, L., Teixeira, C., Preece, G., Kirkham, P. A., and Parkhouse, R. M. E. (1993) J. Immunol. 151, 3119-3130[Abstract] |
| 13. | Lund, F., Solvason, N., Grimaldi, J. C., Parkhouse, R. M. E., and Howard, M. (1995) Immunol. Today 16, 496-473 |
| 14. | Silvennoinen, O., Nishigaki, H., Kitanaka, A., Kumagai, M., Ito, C., Malavasi, F., Lin, Q., Conley, M. E., and Campana, D. (1996) J. Immunol. 156, 100-107[Abstract] |
| 15. |
Kontani, K.,
Kukimoto, I.,
Nishina, H.,
Hoshino, S.,
Hozeki, O.,
Konaho, Y.,
and Katada, T.
(1996)
J. Biol. Chem.
271,
1534-1537 |
| 16. |
Kikuchi, Y.,
Yasue, T.,
Miyake, K.,
Kimoto, M.,
and Takatsu, K.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
11814-11818 |
| 17. | Zubiaur, M., Izquierdo, M., Terhorst, C., Malavasi, F., and Sancho, J. (1997) J. Immunol. 159, 193-205[Abstract] |
| 18. | Litvin, D. A., and Rosenstreich, D. L. (1984) Methods Enzymol. 108, 298-302[Medline] [Order article via Infotrieve] |
| 19. |
Choi, Y. B.,
Kim, C. K.,
and Yun, Y.
(1999)
J. Immunol.
163,
5242-5249 |
| 20. |
Joung, I.,
Strominger, J. L.,
and Shin, J.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
5991-5995 |
| 21. | Izquierdo, P. M., Reif, K., and Cantrell, D. (1995) Immunol. Today 16, 159-164[CrossRef][Medline] [Order article via Infotrieve] |
| 22. | Wange, R. L., and Samelson, L. E. (1996) Immunity 5, 197-205[CrossRef][Medline] [Order article via Infotrieve] |
| 23. | Anderson, S. J., Levin, S. D., and Perlmutter, R. M. (1993) Nature 365, 552-554[CrossRef][Medline] [Order article via Infotrieve] |
| 24. |
Hashimoto, K.,
Sohn, S. J.,
Levin, S. D.,
Tada, L. T.,
Perlmetter, R. M.,
and Nakayama, T.
(1996)
J. Exp. Med.
184,
931-943 |
| 25. | Pawson, T., and Schlessinger, J. (1993) Curr. Biol. 3, 434-442[CrossRef][Medline] [Order article via Infotrieve] |
| 26. | Pawson, T., and Gish, G. D. (1992) Cell 71, 359-362[CrossRef][Medline] [Order article via Infotrieve] |
| 27. |
Park, I.,
Chung, J.,
Walsh, C.,
Yun, Y.,
Strominger, J. L.,
and Shin, J.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
12338-12342 |
| 28. |
Raffel, G. D.,
Parmar, K.,
and Rosenberg, N.
(1996)
J. Biol. Chem.
271,
4640-4645 |
| 29. |
He, T. C.,
Jiang, N.,
Zhuang, H.,
and Wojchowski, D. M.
(1995)
J. Biol. Chem.
270,
11055-11061 |
| 30. |
Muller, A. J.,
Pendergast, A. M.,
Havlik, M. H.,
Puil, L.,
Pawson, T.,
and Witte, O. N.
(1992)
Mol. Cell. Biol.
12,
5087-5093 |
| 31. |
Cleghon, V.,
and Morrison, D. K.
(1994)
J. Biol. Chem.
269,
17749-17755 |
| 32. |
Malek, S. N.,
and Desiderio, S.
(1994)
J. Biol. Chem.
269,
33009-33020 |
| 33. |
Malek, S. N.,
Yang, C. H.,
Earnshaw, W. C.,
Kozak, C.,
and Desiderio, S.
(1996)
J. Biol. Chem.
271,
6952-6962 |
| 34. | Geleziunas, R., Bour, S., and Wainberg, M. A. (1994) FASEB J. 8, 593-600[Abstract] |
| 35. |
August, A.,
and Dupont, B.
(1996)
J. Biol. Chem.
271,
10054-10059 |
| 36. |
Hatakeyama, M.,
Kono, T.,
Kobayashi, N.,
Kawahara, A.,
Levin, S. D.,
Perlmutter, R. M.,
and Taniguchi, T.
(1991)
Science
252,
1523-1528 |
| 37. |
Morra, M.,
Zubiaur, M.,
Terhorst, C.,
Sancho, J.,
and Malavasi, F.
(1998)
FASEB J.
12,
581-592 |
| 38. | Ausiello, C. M., Urbani, F., la Sala, A., Funaro, A., and Malavasi, F. (1995) Eur. J. Immunol. 25, 1477-1480[Medline] [Order article via Infotrieve] |
| 39. | Inoue, S.-i., Kontani, K., Tsujimoto, N., Kanda, Y., Hosoda, N., Hoshino, S.-i., Hazeki, O., and Katada, T. (1997) J. Immunol. 159, 5226-5232[Abstract] |
| 40. | Lund, F., Cockayne, D. A., Randall, T. D., Solvason, N., Schuber, F., and Howard, M. C. (1998) Immunol. Rev. 161, 79-93[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
S.-Y. Rah, K.-H. Park, T.-S. Nam, S.-J. Kim, H. Kim, M.-J. Im, and U.-H. Kim Association of CD38 with Nonmuscle Myosin Heavy Chain IIA and Lck Is Essential for the Internalization and Activation of CD38 J. Biol. Chem., February 23, 2007; 282(8): 5653 - 5660. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Deaglio, T. Vaisitti, S. Aydin, E. Ferrero, and F. Malavasi In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia Blood, August 15, 2006; 108(4): 1135 - 1144. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Chen, Y.-G. Chen, P. C. Reifsnyder, W. H. Schott, C.-H. Lee, M. Osborne, F. Scheuplein, F. Haag, F. Koch-Nolte, D. V. Serreze, et al. Targeted Disruption of CD38 Accelerates Autoimmune Diabetes in NOD/Lt Mice by Enhancing Autoimmunity in an ADP-Ribosyltransferase 2-Dependent Fashion. J. Immunol., April 15, 2006; 176(8): 4590 - 4599. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Munoz, M.-d.-C. Navarro, E. J. Pavon, J. Salmeron, F. Malavasi, J. Sancho, and M. Zubiaur CD38 Signaling in T Cells Is Initiated within a Subset of Membrane Rafts Containing Lck and the CD3-{zeta} Subunit of the T Cell Antigen Receptor J. Biol. Chem., December 12, 2003; 278(50): 50791 - 50802. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |